GlassScriptPhysician profile
Adam K Brown
NPI 1629475165
$6,594.37
in general payments reported to CMS, 2019-2025
24 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $3,019 · 2021: $117 · 2022: $1,231 · 2023: $297 · 2024: $615 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,947.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $2,802.68 | 2020 | |
| Paratek Pharmaceuticals, INC. | $1,167.22 | 2020-2025 | Nuzyra |
| Smith+Nephew, INC. | $809.38 | 2019-2025 | Collagenase Santyl, Stravix Pl, Grafix Pl |
| Amgen INC. | $519.04 | 2024-2025 | Krystexxa |
| Nevro Corp. | $319.19 | 2022 | |
| Melinta Therapeutics, LLC | $212.12 | 2022 | |
| Cardiovascular Systems INC. | $159.96 | 2019-2020 | |
| Solventum Corporation | $108.70 | 2024 | Activ.A.C., Kerramax Care |
| Kci USA, INC. | $98.40 | 2022-2023 | Activ.A.C., V.A.C. Dermatac, Promogran Prisma |
| Grt US Holding, INC. | $61.02 | 2022 | |
| Organogenesis INC. | $47.51 | 2021-2022 | |
| Curonix LLC | $45.48 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Tactile Systems Technology INC | $35.19 | 2019-2020 | |
| Convatec INC. | $27.37 | 2019-2020 | |
| Apria Healthcare LLC | $23.72 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $21.55 | 2025 | Easyfuse |
| Hartmann USA, INC. | $21.51 | 2022 | |
| Kerecis Limited | $20.65 | 2022 | |
| Integra Lifesciences Corporation | $20.48 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Medical Device Business Services, INC. | $20.40 | 2025 | Motoband |
| Medela LLC | $19.02 | 2024 | Invia Motion Endure |
| Averitas Pharma INC. | $18.46 | 2023 | Qutenza |
| Nabriva Therapeutics, Plc | $15.32 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.